Source: Annual Congress 2002 - Bronchial responsiveness in asthma and COPD
Disease area: Airway diseases

Abstract

Regular treatment with salmeterol induces tolerance of its protective effects on both early (EAR) and late (LAR) asthmatic responses to allergen challenge in mild asthmatics (Dente, ATS '97), and doesn't prevent the subsequent increase in sputum eosinophils. Glucocorticoids have been proven to protect partially EAR and fully LAR. To evaluate the synergic effects of salmeterol (S, 50 mcg BID) plus fluticasone (F, 125 mcg BID) for 1 week in comparison with placebo treatment. The combined treatment (F+S) had protective effects on both EAR (deltaFEV1%, -33% after placebo vs -10% after S+F, p<0.001) and LAR (-33% after placebo vs -9% after S+F, p<0.001). After placebo, 16 subjects showed a DUAL response (EAR+LAR) and 2 only an isolated EAR. After S+F, 3 subjects maintained a DUAL and 1 an isolated EAR. Baseline sputum eosinophil percentage was low (median and range, 0.6% [0, 14.1]). After placebo, a significant increase in sputum eosinophils 24 h after allergen challenge was found (9.5% [1.1, 31.3], p<0.001 vs baseline). After S+F, a lower increase in sputum eosinophils was found (6.3% [0, 18.1], p<0.01 vs baseline and p<0.05 vs placebo). We conclude that treatment with inhaled S+F has protective effects on allergen-induced asthmatic responses and on eosinophilic inflammation in airways.

Rating:

Share or cite this content

Citations should be made in the following way:
F. L. Dente, M. Tonelli, M. Zingoni, E. Bacci, S. Carnevali, S. Cianchetti, M. DeSantis, E. Masino, M. Taccola, P. L. Paggiaro (Pisa, Italy). Combined treatment with fluticasone plus salmeterol protects against allergen induced asthmatic responses and subsequent increase in sputum eosinophils. Eur Respir J 2002; 20: Suppl. 38, 1203

Member's Comments

No comment yet.

Related content which might interest you: Combined treatment with fluticasone plus salmeterol protects against allergen-induced asthmatic responses better than each drug alone Source: Eur Respir J 2001; 18: Suppl. 33, 349s Year: 2001 Comparison between fluticasone and salmeterol plus fluticasone on functional responses and sputum eosinophilia induced by allergen challenge Source: Eur Respir J 2005; 26: Suppl. 49, 123s Year: 2005 Symptoms, induced sputum eosinophil percentages and treatment with salmeterol or fluticasone in mild asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Low doses of inhaled fluticasone propionate induce sputum eosinophil apoptosis and inhibit IL-5 release in naive symptomatic asthmatics (FLIC19) Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge Source: Eur Respir J 2007; 30: Suppl. 51, 749s Year: 2007 The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004 The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008 Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002 Effect of salmeterol in asthmatic patients with low sputum eosinophils Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Fluticasone does not add to the salmeterol effect on pig-dust induced inflammation in the lower airways Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006 Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002 Fluticasone induces apoptosis in peripheral T-lymphocytes: a comparison between asthmatic and normal subjects Source: Eur Respir J 2002; 19: 257-266 Year: 2002 Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Source: Eur Respir J 2002; 20: 853-858 Year: 2002 Tolerance to the protective effect of salmeterol on allergen challenge in mild untreated asthmatics and in moderate asthmatics on inhaled corticosteroid treatment Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001 Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days Source: Eur Respir J 2002; 20: Suppl. 38, 197s Year: 2002 The acute protective effect of a single dose of fluticasone propionate (FP) on the allergen-induced early asthmatic response in man Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005